Anti-C5 monoclonal antibody
Crovalimab
Brand names: PiaSky
Adult dose
Dose: Weight-based loading and maintenance — refer to BNF/SmPC; SC injection every 4 weeks for maintenance
Route: IV/SC
Frequency: q4w
Clinical pearls
- Paroxysmal nocturnal haemoglobinuria; vaccinate against meningococcal disease ≥2 weeks before initiation
Contraindications
- Active Neisseria meningitidis infection
- Lack of meningococcal vaccination
Side effects
- Infusion-related reactions
- Type III hypersensitivity
- Increased meningococcal infection risk
- Headache
Interactions
- Live vaccines
- Other complement inhibitors
Monitoring
- Signs of meningococcal infection
- LDH
- Haemolysis markers
Reference: BNF; https://bnf.nice.org.uk/drugs/crovalimab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO